The bile duct and liver cancer: ON-treatment surveillance of tumor evolution and response to systemic treatment (BILLIONSTARS) study.
Philip Falk, Sofie Olsson Hau, Hedda Jacobsen...
https://pubmed.ncbi.nlm.nih.gov/40500706/Actively Recruiting
Led by Region Skane · Updated on 2026-08-03
150
Participants Needed
3
Research Sites
156 weeks
Total Duration
Researchers are conducting the BILLIONSTARS study, a prospective, single-arm observational trial focused on patients diagnosed with hepatocellular carcinoma HCC or cholangiocarcinoma CCC who are recommended locoregional interventions such as surgery, ablation, or transarterial chemoembolization, andor antitumoral medical treatments. The study aims to understand how tumor characteristics and individual factors influence treatment response by analyzing blood samples, tumor tissue, and other biological markers. The study plans to enroll 150 patients at specific hospitals and includes research autopsies for patients in late palliative phases. Participants will have blood samples collected before, during, and after systemic treatment to analyze circulating tumor DNA, immune cells, and proteins. Tumor tissue from surgical specimens will be collected mainly as formalin-fixed paraffin-embedded samples, with some fresh tissue stored for future research. Quality of life questionnaires will be completed at the start of the study and at three and six months. Treatments will follow national guidelines and will not be influenced by study participation. Radiological and clinical follow-ups will occur as part of usual care or when clinically necessary. During the study, participants will be monitored through blood sample collections aligned with treatment visits and will complete quality of life assessments. The primary outcome measure is overall survival, assessed up to 60 months. Secondary outcomes include progression-free survival and changes in quality of life using specific questionnaires. The study includes safety and clinical follow-up as per standard protocols, with participation lasting up to several years based on survival and treatment timelines.
CONDITIONS
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
K
Karin Jirström, PhD, MD, professor
P
Philip Falk, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Region Skane
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 60 months
Participants have blood samples collected before, during, and after systemic treatment to analyze tumor DNA and other markers. They complete quality of life questionnaires at study start, three months, and six months. Usual clinical and radiological follow-ups occur according to standard care.
Blood samples and questionnaires collected at treatment visits and specific intervals
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Philip Falk, Sofie Olsson Hau, Hedda Jacobsen...
https://pubmed.ncbi.nlm.nih.gov/40500706/Region Skane
Lead Sponsor